Skip to main content
265 search results for:

Gilteritinib 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 01-04-2024 | Gilteritinib | News

    Gilteritinib

    Cytopenia
  2. 01-04-2024 | Gilteritinib | News

    Gilteritinib

    Thrombotic microangiopathy
  3. 01-04-2024 | Gilteritinib | OriginalPaper

    Gilteritinib combined with venetoclax and azacitidine for relapsed acute myeloid leukemia cocurrent with pure red cell aplasia after allogeneic hematopoietic stem cell transplantation: a case report

    Pure red cell aplasia (PRCA) is a rare bone marrow (BM) disorder characterized by ineffective erythropoiesis, reduced reticulocyte count, normocytic anemia, and the absence of erythroid precursors. Here, we present a rare instance of PRCA …

  4. Open Access 22-08-2023 | Acute Myeloid Leukemia | OriginalPaper

    Gilteritinib and the risk of intracranial hemorrhage: a case series of a possible, under-reported side effect

    A case series of five patients with  FLT3 -mutated acute myeloid leukemia who developed intracranial hemorrhage within the first month of exposure to gilteritinib.

  5. 01-11-2023 | Gilteritinib | News

    Gilteritinib/quizartinib/sorafenib

    Lack of efficacy following off-label use: 3 case reports
  6. 01-09-2023 | Gilteritinib | News

    Gilteritinib/sorafenib

    Enteritis following off-label use and dermal toxicity: case report
  7. 01-07-2023 | Gilteritinib | News

    Gilteritinib/isavuconazonium/voriconazole

    Various toxicities, drug interaction and lack of efficacy: 5 case reports
  8. 01-09-2021 | Acute Myeloid Leukemia | News

    Gilteritinib

    Grade 3 liver damage: case report
  9. 01-05-2021 | Gilteritinib | News

    Gilteritinib/hydroxycarbamide/remdesivir

    Neutropenia, lack of efficacy and off-label use: case report
  10. Open Access 01-12-2021 | Gilteritinib | OriginalPaper

    Acute cardiotoxicity after initiation of the novel tyrosine kinase inhibitor gilteritinib for acute myeloid leukemia

    Constitutive activation of FMS-like tyrosine kinase 3 (FLT3) occurs in approximately 30% of acute myeloid leukemias (AML) and is clinically associated with an aggressive disease course and higher rates of relapse [ 1 , 2 ]. FLT3 inhibitors have …

  11. Open Access 01-11-2021 | Acute Myeloid Leukemia | OriginalPaper

    Gilteritinib versus chemotherapy in Japanese patients with FLT3-mutated relapsed/refractory acute myeloid leukemia

    Acute myeloid leukemia (AML) is the most common leukemia among Japanese adults, and accounts for approximately 70% of all myeloid leukemias [ 1 , 2 ]. Patients with relapsed AML have a poor prognosis, with a 5-year survival rate of 10–11% [ 3 , 4 …

  12. 01-04-2023 | Acute Myeloid Leukemia | News

    Gilteritinib/vancomycin

    Various toxicities, lack of efficacy and off label use: 6 case reports
  13. 01-02-2022 | Prostate Cancer | Letter

    A case report of combined treatment of gilteritinib and LH-RH agonist for Fms-related tyrosine kinase 3 receptor mutation-positive acute myeloid leukemia and bone marrow metastasis of prostate cancer

  14. 01-04-2020 | Acute Myeloid Leukemia | News

    Gilteritinib

    Hypothyroidism presenting as a large pericardial effusion: case report
  15. Open Access 01-10-2020 | Acute Myeloid Leukemia | OriginalPaper

    Pharmacokinetic Profile of Gilteritinib: A Novel FLT-3 Tyrosine Kinase Inhibitor

    Over 90% of leukemia cases are diagnosed in adults 20 years of age and older, among whom the most common types are chronic lymphocytic leukemia (37%) and acute myeloid leukemia (AML; 32%). [ 1 ] It was estimated that 19,520 patients (10,380 men and …

  16. 01-10-2020 | Acute Myeloid Leukemia | ReviewPaper

    Gilteritinib: A Review in Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukaemia

    Gilteritinib (Xospata®), a next-generation tyrosine kinase inhibitor (TKI), is approved in several countries/regions worldwide for the treatment of relapsed or refractory acute myeloid leukaemia (AML) in adults with FMS-like tyrosine kinase 3 …

  17. 01-08-2020 | Acute Myeloid Leukemia | OriginalPaper

    Successful treatment with gilteritinib for isolated extramedullary relapse of acute myeloid leukemia with FLT3-ITD mutation after allogeneic stem cell transplantation

    Acute myeloid leukemia (AML) harboring Fms-like tyrosine kinase 3 (FLT3) internal tandem duplication (ITD) mutation is associated with shorter remission and higher relapse risk. Several FLT3 inhibitors have been used in clinical trials, but their …

  18. 01-03-2022 | Acute Myeloid Leukemia | News

    Gilteritinib

    Acute systolic heart failure and inflammatory cardiomyopathy: case report
  19. 01-03-2022 | Acute Myeloid Leukemia | News

    Gilteritinib

    Liver injury: case report
  20. 01-08-2020 | Acute Myeloid Leukemia | OriginalPaper

    Durable remission of post-transplant relapsed FLT3-ITD AML in response to gilteritinib administration after a second transplant from the same donor

    Patients with FMS-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD) acute myeloid leukemia (AML) respond to conventional induction chemotherapy, with remission rates similar to those seen in other subtypes; however, they are much more …

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.